Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.

Clinical Trial Description

Long QT syndrome (LQTS) is a genetic disorder characterized by prolongation of the QT interval in the electrocardiogram (ECG) and a propensity to torsade de pointes ventricular tachycardia frequently leading to syncope, cardiac arrest, or sudden death usually in young otherwise healthy individuals. The long QT syndrome is caused by mutations of predominantly potassium and sodium ion channel genes or channel-related proteins. The most common types of LQTS affect: the slow delayed rectifier potassium repolarization channel (KCNQ1; LQT1) resulting in a reduction in IKs current; the rapid delayed rectifying potassium repolarization channel (KCNH2; LQT2) resulting in a reduction in IKr current; and the sodium channel (SCN5A; LQT3) resulting in an increase in late INa current. Among positively genotyped patients, LQT1 and LQT2 account for about 90% of LQTS cases, whereas LQT3 accounts for about 5% to 8% of cases. LQT3 patients represent a challenging cohort of patients. Unlike patients with LQT1 and LQT2 form of this disorder, the LQT3 patients have high lethality of cardiac events with 1 in 5 patients dying suddenly during their first syncopal or arrhythmic event. In childhood (age 0-18) in the analysis of 1,404 patients, LQT3 was found to be associated with significantly higher risk of aborted cardiac arrest or death than LQT1 and LQT2. A similar pattern is observed in LQTS patients after age 40 in whom LQT3 patients show the highest risk. Optimal therapy in LQT3 patients remains controversial. There are data showing that sodium current blockers including mexiletine and flecainide shorten QTc duration in LQT3 patients. Ranolazine is a selective late sodium current inhibitor that has been also showed to reduce QTc in DKPQ mutation and D1790G mutation patients. However, data on long-term effectiveness of ranolazine are limited. This single-blinded study evaluated a long-term effects of ranolazine on QTc duration in LQT3 patients with various LQT3 mutations. Enrolled subjects are treated for 1 months with matching placebo and next for subsequent 5 months with ranolazine with ECG recorded at baseline, 1 , 2, and 6 months of follow-up. ;

Study Design

Related Conditions & MeSH terms

Long QT Syndrome

Clinical Trial Details

NCT number	NCT01648205
Study type	Interventional
Source	University of Rochester
Contact
Status	Completed
Phase	Phase 2
Start date	September 2012
Completion date	July 20, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04169100` - Novel Form of Acquired Long QT Syndrome	Phase 4
Recruiting	`NCT06087367` - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting	`NCT04675788` - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening	Phase 4
Completed	`NCT05759962` - Phase 1 Study of LQT-1213 in Healthy Adults	Phase 1
Enrolling by invitation	`NCT05903313` - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated	`NCT02439645` - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Completed	`NCT04706104` - QT Measurement Techniques and Anesthesia Management
Recruiting	`NCT04336644` - Continuous Versus Intermittent cARdiac Electrical moNitorinG	N/A
Recruiting	`NCT02814981` - Hydroxyzine and Risk of Prolongation of QT Interval	N/A
Completed	`NCT02876380` - Prospective Identification of Long QT Syndrome in Fetal Life
Completed	`NCT02425189` - The Canadian National Long QT Syndrome Registry
Completed	`NCT00399412` - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients	N/A
Completed	`NCT02513940` - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes	Phase 4
Completed	`NCT02441829` - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function	Phase 1
Completed	`NCT03182777` - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies	N/A
Completed	`NCT01849003` - Study of the Effect of GS-6615 in Subjects With LQT-3	Phase 1
Completed	`NCT00316459` - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects	Phase 1
Completed	`NCT00292032` - Registry of Unexplained Cardiac Arrest
Recruiting	`NCT05348564` - Comparing Direct vs Indirect Methods for Cascade Screening	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.